These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 24118434)

  • 1. Interaction of disulfiram with antiretroviral medications: efavirenz increases while atazanavir decreases disulfiram effect on enzymes of alcohol metabolism.
    McCance-Katz EF; Gruber VA; Beatty G; Lum P; Ma Q; DiFrancesco R; Hochreiter J; Wallace PK; Faiman MD; Morse GD
    Am J Addict; 2014; 23(2):137-44. PubMed ID: 24118434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of ritonavir, atazanavir and their combination on the CYP3A4 induction potential of efavirenz in primary human hepatocytes.
    Mugundu GM; Hariparsad N; Desai PB
    Drug Metab Lett; 2010 Jan; 4(1):45-50. PubMed ID: 20201776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. S-methyl-N,N-diethylthiocarbamate sulfoxide and S-methyl-N,N-diethylthiocarbamate sulfone, two candidates for the active metabolite of disulfiram.
    Mays DC; Nelson AN; Lam-Holt J; Fauq AH; Lipsky JJ
    Alcohol Clin Exp Res; 1996 May; 20(3):595-600. PubMed ID: 8727261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study.
    Dumond JB; Adams JL; Prince HM; Kendrick RL; Wang R; Jennings SH; Malone S; White N; Sykes C; Corbett AH; Patterson KB; Forrest A; Kashuba AD
    HIV Med; 2013 Aug; 14(7):401-9. PubMed ID: 23433482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patients.
    Josephson F; Andersson MC; Flamholc L; Gisslén M; Hagberg L; Ormaasen V; Sönnerborg A; Vesterbacka J; Böttiger Y
    Eur J Clin Pharmacol; 2010 Apr; 66(4):349-57. PubMed ID: 19967342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir.
    Bifano M; Hwang C; Oosterhuis B; Hartstra J; Grasela D; Tiessen R; Velinova-Donga M; Kandoussi H; Sevinsky H; Bertz R
    Antivir Ther; 2013; 18(7):931-40. PubMed ID: 23963204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic interactions of CEP-1347 and atazanavir in HIV-infected patients.
    Ma Q; Gelbard HA; Maggirwar SB; Dewhurst S; Gendelman HE; Peterson DR; DiFrancesco R; Hochreiter JS; Morse GD; Schifitto G
    J Neurovirol; 2013 Jun; 19(3):254-60. PubMed ID: 23737347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population Pharmacokinetics Modeling of Unbound Efavirenz, Atazanavir, and Ritonavir in HIV-Infected Subjects With Aging Biomarkers.
    Dumond JB; Chen J; Cottrell M; Trezza CR; Prince H; Sykes C; Torrice C; White N; Malone S; Wang R; Patterson KB; Sharpless NE; Forrest A
    CPT Pharmacometrics Syst Pharmacol; 2017 Feb; 6(2):128-135. PubMed ID: 28032946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of oral posaconazole on the pharmacokinetics of atazanavir alone and with ritonavir or with efavirenz in healthy adult volunteers.
    Krishna G; Moton A; Ma L; Martinho M; Seiberling M; McLeod J
    J Acquir Immune Defic Syndr; 2009 Aug; 51(4):437-44. PubMed ID: 19623694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status.
    Mollan K; Daar ES; Sax PE; Balamane M; Collier AC; Fischl MA; Lalama CM; Bosch RJ; Tierney C; Katzenstein D;
    J Infect Dis; 2012 Dec; 206(12):1920-30. PubMed ID: 23148287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo pharmacodynamic studies of the disulfiram metabolite S-methyl N,N-diethylthiolcarbamate sulfoxide: inhibition of liver aldehyde dehydrogenase.
    Hart BW; Faiman MD
    Alcohol Clin Exp Res; 1994 Apr; 18(2):340-5. PubMed ID: 8048736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo inhibition of rat liver aldehyde dehydrogenase by S-methyl N,N-diethylthiolcarbamate sulfoxide, a new metabolite of disulfiram.
    Hart BW; Faiman MD
    Biochem Pharmacol; 1992 Feb; 43(3):403-6. PubMed ID: 1311578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. S-methyl-N,N-diethylthiolcarbamate: a disulfiram metabolite and potent rat liver mitochondrial low Km aldehyde dehydrogenase inhibitor.
    Hart BW; Yourick JJ; Faiman MD
    Alcohol; 1990; 7(2):165-9. PubMed ID: 2158327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioactivation of S-methyl N,N-diethylthiolcarbamate to S-methyl N,N-diethylthiolcarbamate sulfoxide. Implications for the role of cytochrome P450.
    Hart BW; Faiman MD
    Biochem Pharmacol; 1993 Dec; 46(12):2285-90. PubMed ID: 8274162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavir.
    Pham PA; Flexner C; Parsons T; Vasist L; Fuchs E; Carson K; Agarwala S; Barditch-Crovo P
    J Acquir Immune Defic Syndr; 2007 Jun; 45(2):201-5. PubMed ID: 17414932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies.
    Schipani A; Dickinson L; Boffito M; Austin R; Owen A; Back D; Khoo S; Davies G
    J Acquir Immune Defic Syndr; 2013 Jan; 62(1):60-6. PubMed ID: 23011396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disulfiram metabolism as a requirement for the inhibition of rat liver mitochondrial low Km aldehyde dehydrogenase.
    Yourick JJ; Faiman MD
    Biochem Pharmacol; 1991 Sep; 42(7):1361-6. PubMed ID: 1656985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir.
    McComsey GA; Kitch D; Daar ES; Tierney C; Jahed NC; Melbourne K; Ha B; Brown TT; Bloom A; Fedarko N; Sax PE
    AIDS; 2012 Jul; 26(11):1371-85. PubMed ID: 22546988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers.
    Burger DM; Agarwala S; Child M; Been-Tiktak A; Wang Y; Bertz R
    Antimicrob Agents Chemother; 2006 Oct; 50(10):3336-42. PubMed ID: 17005814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach.
    Siccardi M; Marzolini C; Seden K; Almond L; Kirov A; Khoo S; Owen A; Back D
    Clin Pharmacokinet; 2013 Jul; 52(7):583-92. PubMed ID: 23479398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.